

ENGINEERED TRYPTOPHAN DECARBOXYLASES AND USES THEREOF FOR SYNTHESIZING TRYPTAMINE ANALOGS

View U.S. Patent Application Publication No. US-2023-0357744 in PDF format.

WARF: P220120US02

Inventors: Andrew Buller, Allwin McDonald

The Invention

UW-Madison researchers have identified several tryptophan decarboxylase (TDC) mutations for improving enzymatic activity towards substituted tryptamines. Having identified these mutations, the researchers generated RgnTDC mutants via heterologous expression, enabling efficient production of these mutants for use as biocatalysts at scale. Finally, the researchers established the utility of these mutations in multiple formats including, whole-cell, single-enzyme, and multi-enzyme cascades.

Additional Information

For More Information About the Inventors

Andrew Buller

Tech Fields

- Drug Discovery & Development : Other drug discovery & development
- Research Tools : Biomanufacturing

For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. See our privacy policy

